Your browser doesn't support javascript.
loading
Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
Coelingh Bennink, Herjan J T; Zimmerman, Yvette; Laan, Ellen; Termeer, Hanneke M M; Appels, Nicole; Albert, Adelin; Fauser, Bart C J M; Thijssen, Jos H H; van Lunsen, Rik H W.
Afiliação
  • Coelingh Bennink HJT; Pantarhei Bioscience, Zeist, The Netherlands.
  • Zimmerman Y; Pantarhei Bioscience, Zeist, The Netherlands. Electronic address: yz@pantarheibio.com.
  • Laan E; Department of Sexology and Psychosomatic Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, The Netherlands.
  • Termeer HMM; Department of Sexology and Psychosomatic Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, The Netherlands.
  • Appels N; Pantarhei Bioscience, Zeist, The Netherlands.
  • Albert A; Department of Biostatistics, University Hospital of Liege, Belgium.
  • Fauser BCJM; Department of Reproductive Medicine & Gynecology, University Medical Center Utrecht, The Netherlands.
  • Thijssen JHH; Department of Endocrinology, University Medical Center Utrecht, The Netherlands.
  • van Lunsen RHW; Department of Sexology and Psychosomatic Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, The Netherlands.
Contraception ; 96(5): 322-329, 2017 Nov.
Article em En | MEDLINE | ID: mdl-27393080
ABSTRACT

OBJECTIVE:

To determine whether adding dehydroepiandrosterone to combined oral contraceptives (COCs) maintains physiological levels of free testosterone. STUDY

DESIGN:

A randomized, double-blind, placebo-controlled, two-way crossover study conducted in 81 healthy women (age range 20-35 years; Body mass index (BMI) range 18-35 kg/m2) using oral contraceptives. Androgens, sex hormone-binding globulin (SHBG), estradiol (E2) and estrone (E1) were measured, and free testosterone and the free testosterone index were calculated. Subjects discontinued oral contraceptive use for at least one menstrual cycle before being randomized to receive five cycles of ethinyl estradiol (EE) combined with either levonorgestrel (EE/LNG group) or drospirenone (EE/DRSP group) together with either dehydroepiandrosterone (DHEA) (50 mg/day orally) or placebo. Subsequently, all subjects crossed over to the other treatment arm for an additional five cycles.

RESULTS:

Both COCs decreased the levels of all androgens measured. Significant decreases (p<.05) were found with EE/LNG and EE/DRSP for total testosterone (54.5% and 11.3%, respectively) and for free testosterone (66.8% and 75.6%, respectively). Adding DHEA to the COCs significantly increased all androgens compared to placebo. Moreover, including DHEA restored free testosterone levels to baseline values in both COC groups and total testosterone levels to baseline in the EE/LNG group and above baseline in the EE/DRSP group. SHBG concentrations were significantly higher with EE/DRSP compared to EE/LNG (p<.0001). The addition of DHEA did not affect the levels of SHBG.

CONCLUSIONS:

Taking COCs reduces total and free testosterone levels and increases SHBG concentrations. By coadministration with DHEA, physiological levels of total and free testosterone are restored while using EE/LNG. With EE/DRSP, only the free testosterone level is normalized by DHEA coadministration. IMPLICATIONS A daily oral dose of 50-mg DHEA maintains physiological free and total testosterone levels in women who are using an EE/LNG-containing COC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testosterona / Desidroepiandrosterona / Anticoncepcionais Orais Combinados / Anticoncepcionais Orais Hormonais Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans País/Região como assunto: Europa Idioma: En Revista: Contraception Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testosterona / Desidroepiandrosterona / Anticoncepcionais Orais Combinados / Anticoncepcionais Orais Hormonais Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans País/Região como assunto: Europa Idioma: En Revista: Contraception Ano de publicação: 2017 Tipo de documento: Article